We’re setting the pace for future drug discovery by driving innovation from within
Over a century has passed since the discovery of insulin. Despite, being a life-saver drug and the first approved biologic, only three approved analogues carry incremental changes from natural insulins. We are carrying out a receptor-driven design strategy to obtain insulin variants that possess novel, desirable properties due to significant changes to the peptide backbone.
Long-acting oral insulin
An effective and viable oral insulin has been a “holy grail” quest in insulin research. Patient convenience leading to earlier initiation of insulin therapy and the restoration of a physiological insulin distribution are the primary drivers for oral insulins. Poor resistance to gut enzymes and low bioavailability have been the primary stumbling blocks for the same.
Cold chain requirements for insulin transport and storage add to the cost of this vital therapeutic and limits access in less developed geographies. A thermostable insulin that mimics the properties of human insulin would greatly benefit a larger number of people by reducing cost and allowing for penetration in remote regions.
Insulin GLP1 dual agonist
Currently, there are no reported peptides that are able to activate both the insulin and incretin pathways. Creating such a molecule represents a major challenge as they bind to completely unrelated targets. We are designing such a molecule using our innovative insulin engineering strategy and a breakthrough would open up an entirely new space for diabetes management.